0.53
Precedente Chiudi:
$0.492
Aprire:
$0.49
Volume 24 ore:
6.28M
Relative Volume:
0.95
Capitalizzazione di mercato:
$114.11M
Reddito:
$52.29M
Utile/perdita netta:
$-134.84M
Rapporto P/E:
-0.7067
EPS:
-0.75
Flusso di cassa netto:
$-117.11M
1 W Prestazione:
+13.98%
1M Prestazione:
-13.40%
6M Prestazione:
-73.63%
1 anno Prestazione:
-10.43%
Sangamo Therapeutics Inc Stock (SGMO) Company Profile
Nome
Sangamo Therapeutics Inc
Settore
Industria
Telefono
(510) 970-6000
Indirizzo
501 CANAL BLVD., RICHMOND, CA
Confronta SGMO con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
SGMO
Sangamo Therapeutics Inc
|
0.53 | 114.11M | 52.29M | -134.84M | -117.11M | -0.75 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Sangamo Therapeutics Inc Stock (SGMO) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2024-12-13 | Aggiornamento | Truist | Hold → Buy |
2024-12-10 | Reiterato | H.C. Wainwright | Buy |
2023-11-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
2023-04-28 | Downgrade | BofA Securities | Neutral → Underperform |
2023-02-27 | Aggiornamento | Wedbush | Neutral → Outperform |
2023-01-06 | Downgrade | BofA Securities | Buy → Neutral |
2022-06-13 | Ripresa | Wedbush | Neutral |
2021-05-04 | Iniziato | RBC Capital Mkts | Outperform |
2021-01-07 | Ripresa | Guggenheim | Neutral |
2021-01-06 | Iniziato | Stifel | Hold |
2020-12-16 | Ripresa | H.C. Wainwright | Buy |
2020-09-08 | Iniziato | BofA Securities | Buy |
2020-07-07 | Iniziato | SunTrust | Buy |
2019-08-26 | Iniziato | H.C. Wainwright | Buy |
2018-11-14 | Downgrade | JP Morgan | Overweight → Neutral |
2018-11-09 | Downgrade | Guggenheim | Buy → Neutral |
2018-10-10 | Iniziato | Guggenheim | Buy |
2018-06-20 | Iniziato | BofA/Merrill | Buy |
2017-11-15 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
2017-06-22 | Ripresa | Jefferies | Buy |
2016-11-01 | Downgrade | Wedbush | Outperform → Neutral |
2016-10-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
2015-12-04 | Iniziato | Wells Fargo | Outperform |
2015-10-23 | Ripresa | Jefferies | Buy |
2013-05-03 | Iniziato | BioLogic Equity Research | Sell |
2011-02-23 | Reiterato | JMP Securities | Mkt Outperform |
2010-07-29 | Reiterato | Wedbush | Outperform |
2009-10-19 | Iniziato | Brean Murray | Sell |
2009-10-07 | Reiterato | Leerink Swann | Outperform |
2009-08-25 | Reiterato | JMP Securities | Mkt Outperform |
Mostra tutto
Sangamo Therapeutics Inc Borsa (SGMO) Ultime notizie
H.C. Wainwright Maintains Buy Rating on Sangamo Therapeutics (SGMO) - MSN
5 Best Stem Cell Companies to Invest In (June 2025) - Securities.io
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World
Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering - Zenopa
Sangamo Therapeutics’ SWOT analysis: genomic medicine firm faces cash crunch - Investing.com
Lazard Asset Management LLC Takes Position in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) - Defense World
Captrust Financial Advisors Makes New $30,000 Investment in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) - Defense World
StockNews.com Initiates Coverage on Sangamo Therapeutics (NASDAQ:SGMO) - Defense World
Barclays Issues Pessimistic Forecast for Sangamo Therapeutics (NASDAQ:SGMO) Stock Price - Defense World
Sangamo Biosciences’ Earnings Call: Progress Amid Challenges - TipRanks
Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates - MSN
Barclays Updates Price Target for Sangamo Therapeutics (SGMO) | SGMO Stock News - GuruFocus
Sangamo (SGMO) Price Target Reduced by Barclays | SGMO Stock New - GuruFocus
Sangamo Biosciences Announces $23 Million Share Offering - TipRanks
Barclays Updates Price Target for Sangamo Therapeutics (SGMO) | - GuruFocus
Sangamo Therapeutics (SGMO) Projects 2025 Operating Expenses Ami - GuruFocus
Sangamo Therapeutics Inc (SGMO) Q1 2025 Earnings Call Highlights: Strategic Partnerships and ... - Yahoo Finance
Sangamo Therapeutics Inc (SGMO) Q1 2025 Earnings Call Highlights - GuruFocus
Sangamo Therapeutics prices $23M securities offering - MSN
Market Setbacks: Major Stocks Face Financial Hurdles - Finimize
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q1 2025 Earnings Call Transcript - Insider Monkey
Sangamo Therapeutics (SGMO) Announces $23M Capital Raise - GuruFocus
Sangamo Therapeutics (SGMO) Reports First Quarter Revenue Below - GuruFocus
Sangamo Therapeutics (SGMO) Q1 Earnings Miss Expectations - GuruFocus
Sangamo Therapeutics Postpones First Quarter 2025 Conference Call to Later the Same Day - BioSpace
Sangamo Therapeutics Reports Q1 2025 Progress and Financials - TipRanks
Sangamo Therapeutics Q1 2025 Earnings Call Transcript - MarketBeat
Transcript : Sangamo Therapeutics, Inc., Q1 2025 Earnings Call, May 12, 2025 - marketscreener.com
Earnings call transcript: Sangamo Therapeutics faces stock drop after Q1 2025 call - Investing.com Nigeria
Sangamo Therapeutics Reports Recent Business Highlights and Firs - GuruFocus
Sangamo Therapeutics (SGMO) Reports First Quarter Revenue Below Expectations | SGMO Stock News - GuruFocus
Sangamo Therapeutics Announces Pricing of $23.0 Million Underwri - GuruFocus
Sangamo Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Sangamo Therapeutics, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:SGMO) - Seeking Alpha
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results | SGMO Stock News - GuruFocus
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results - BioSpace
Sangamo: Q1 Earnings Snapshot - San Antonio Express-News
Sangamo Therapeutics Announces First Quarter 2025 Earnings Call - Zenopa
Sangamo Therapeutics (SGMO) Anticipates Q1 Earnings Release - GuruFocus
Sangamo hits milestone toward accelerated approval for ST-920 - Fabry Disease News
Sangamo Therapeutics Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry Disease - BioSpace
Sangamo Biosciences Receives Nasdaq Deficiency Notice - TipRanks
Sangamo Therapeutics Inc Azioni (SGMO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):